

24 Jan 2021 |

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by *Scrip's* global team, in this mini podcast version of Five Must-Know Things.

This episode includes insights from around the biopharma world for the business week ended 22 January 2021.

This time we have more from JPM including mid-term launch plans from a UK major and how successful the virtual format was, contingency plans for a single-dose coronavirus vaccine, an antibody for COVID-19, and a roundup of the industry's own views of its prospects for the coming year.

LISTEN ON



Spotify®

## *Scrip Podcasts Now On Spotify!*

Listen to the latest industry news, analysis and opinion from our editorial team on Spotify.

[Listen on Spotify](#)

These and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Play, SoundCloud and TuneIn - and now on [Spotify Podcasts](#) - and also via smart speakers if one of these channels has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[GSK Aims To Launch 13 Blockbusters In Five Years](#)" - Scrip, 18 Jan, 2021.)

(Also see "[J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business](#)" - Scrip, 14 Jan, 2021.)

(Also see "[J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints](#)" - Scrip, 15 Jan, 2021.)

(Also see "[Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab](#)" - Scrip, 20 Jan, 2021.)

(Also see "[Scrip Asks... What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19](#)" - Scrip, 18 Jan, 2021.)

[Click here to explore this interactive content online](#) ✎